What is the significance of the 12-month extension given to Pharma units to implement the revised Schedule M of Drugs and Cosmetics Act
Pharma units get 12-month extension to implement revised Schedule M of Drugs and Cosmetics Act
- Implementation of the revised Schedule M of the Drugs and Cosmetics Act is crucial for ensuring the quality and safety of pharmaceutical products.
- The 12-month extension provides pharmaceutical units with additional time to make necessary changes to comply with the new regulations.
- It allows the units to review their processes, facilities, and documentation to meet the updated standards for manufacturing pharmaceutical products.
- This extension can help reduce the burden on pharmaceutical companies and prevent disruptions in the supply of essential medicines to the market.
- Compliance with the revised Schedule M requirements is essential to maintain the reputation of the pharmaceutical industry and ensure consumer trust in the quality of drugs.
Answered
4 months ago